Gastric Cancer News and Research

RSS

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

Australian scientists sequence genome of pancreatic cancer

The International Cancer Genome Consortium which includes researchers from 22 countries is mapping the genomes of different types of cancers. A genome is essentially a blueprint of a human’s DNA. The genetic data of each individual is different and so is the genetic data of the cancer in the individual. The Australian scientists are sequencing the genomes of people suffering from pancreatic cancer.

15 Apr 2010

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

Link between IL-8, MIF gene polymorphisms and progression of atrophic gastritis and intestinal metaplasia

Atrophic gastritis and intestinal metaplasia are two important precursory lesions in the process of intestinal type gastric cancer. However, the precise mechanism of the progression of these two lesions is still unclear, a few studies have investigated the risk of host gene polymorphism on the atrophic gastritis and intestinal metaplasia, but all of them are limited by their one-time point screen.

13 Apr 2010

Rosetta Genomics to present posters on microRNA-based technologies at AACR 2010

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research's 101st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010.

12 Apr 2010

A*STAR announces fifth major collaboration with Italian research centres and universities

Two research units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy's Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will potentially help millions of cancer and bone loss patients across the world. This is the fifth major collaboration A*STAR has with research centres and universities in Italy .

9 Apr 2010

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

Gastric cancer in Mexico is the most frequent gastrointestinal malignant neoplasm. Several precursor conditions, such as chronic gastritis, have been associated with the development of gastric cancer. The gelatinases MMP-2 and MMP-9, members of the metalloproteinase family, are fundamental enzymes in extracellular matrix remodelling. The extracellular matrix is composed of secreted molecules outside cells which provides structural support and regulates cell behaviour.

9 Apr 2010

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

Hormone ghrelin may improve appetite in gastric cancer patients

In gastric cancer patients who have had part or all of their stomach removed, the hormone ghrelin may lessen post-operative weight loss and improve appetite, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

1 Apr 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

Self-rated quality of life predicts long-term survival for esophago-gastric cancer

Changes in patients' self-rated quality of life after treatment for esophago-gastric cancer can predict the chances for long-term survival. This is the result researchers at the Swedish medical university Karolinska Institutet made, in a new study published in the Journal of Clinical Oncology.

9 Mar 2010

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.

9 Mar 2010

Combination of two targeted therapies effective against subset of gastric cancers: Study

A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

3 Mar 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Lilly, Merck, Pfizer collaborate to accelerate research on commonly-diagnosed cancer

Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.

23 Feb 2010

Insight into mechanism H. pylori uses to evade the immune system

Helicobacter pylori (H. pylori) is the causal agent of chronic gastritis, ulcer and gastric cancer. It has the potential to persist in the human stomach for decades, sometimes causing neither harm nor clinical symptoms. Nevertheless, on some occasions, depending on the host immune system and the strain causing the infection, the outcome can be very serious. To maintain the infection, the bacterium must adapt to survive the host defences. One way to accomplish this is to sequentially change the external proteins on the bacterial surface.

10 Feb 2010

Gastric Cancer News and Research

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

ICGC: New era of personalised medicine for cancer patients

Australian scientists sequence genome of pancreatic cancer

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Link between IL-8, MIF gene polymorphisms and progression of atrophic gastritis and intestinal metaplasia

Rosetta Genomics to present posters on microRNA-based technologies at AACR 2010

A*STAR announces fifth major collaboration with Italian research centres and universities

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Hormone ghrelin may improve appetite in gastric cancer patients

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Antibiotics lower risk of developing gastric cancer

Self-rated quality of life predicts long-term survival for esophago-gastric cancer

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Combination of two targeted therapies effective against subset of gastric cancers: Study

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Lilly, Merck, Pfizer collaborate to accelerate research on commonly-diagnosed cancer

Insight into mechanism H. pylori uses to evade the immune system

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News